Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

Table 2 Prevalence of adverse events after beginning sorafenib, according to CTCAE version 5.0, n (%)

	Group A (n = 41)				Group B (n = 30)				Group C (n = 63)
	All grades	Grade 1	Grade 2	Grade 3	All grades	Grade 1	Grade 2	Grade 3	All grades	Grade 1	Grade 2	Grade 3
Any adverse event	37 (90.2)	30 (73.2)	18 (43.9)	5 (12.2)	30 (100)	28 (93.3)	24 (80.0)	14 (46.6)	63 (100)	58 (92.1)	36 (57.1)	14 (22.2)
Hand-foot skin reaction	0 (0)	0 (0)	0 (0)	0 (0)	30 (100)	15 (50.0)	10 (33.3)	5 (16.7)	63 (100)	39 (61.9)	19 (30.2)	5 (7.9)
Anemia	17 (41.5)	8 (19.5)	8 (19.5)	1 (2.4)	20 (66.6)	13 (43.3)	4 (13.3)	3 (10.0)	23 (36.5)	14 (22.2)	7 (11.1)	2 (3.2)
Diarrhea	15 (36.6)	12 (29.3)	3 (7.3)	0 (0)	11 (36.6)	9 (30.0)	1 (3.3)	1 (3.3)	27 (42.8)	21 (33.3)	2 (3.2)	4 (6.3)
Fatigue	14 (34.1)	10 (26.8)	3 (7.3)	0 (0)	11 (36.6)	7 (23.3)	4 (13.3)	0 (0)	16 (25.4)	10 (15.9)	6 (9.5)	0 (0)
Anorexia	14 (34.1)	10 (24.4)	3 (7.3)	1 (2.4)	7 (23.3)	5 (16.7)	1 (3.3)	1 (3.3)	19 (30.1)	15 (23.8)	4 (6.3)	0 (0)
Hypertension	12 (29.3)	10 (24.4)	2 (4.9)	0 (0)	7 (23.3)	2 (6.6)	5 (16.7)	0 (0)	23 (36.5)	16 (25.4)	4 (6.3)	3 (4.8)
Thrombocytopenia	9 (22.0)	2 (4.9)	4 (9.7)	3 (7.3)	23 (76.7)	10 (33.3)	8 (26.7)	5 (16.7)	20 (31.7)	10 (15.9)	5 (7.9)	5 (7.9)
Alopecia	6 (14.6)	4 (9.7)	2 (4.9)	0 (0)	2 (6.6)	2 (6.6)	0 (0)	0 (0)	20 (31.7)	19 (30.2)	1 (1.6)	0 (0)
Hepatic encephalopathy	1 (2.4)	0 (0)	1 (2.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)